61.87
+2.1(+3.51%)
Currency In USD
| Previous Close | 59.77 |
| Open | 59.83 |
| Day High | 62.59 |
| Day Low | 59.35 |
| 52-Week High | 111.29 |
| 52-Week Low | 47.25 |
| Volume | 1.29M |
| Average Volume | 1.37M |
| Market Cap | 4.23B |
| PE | 25.67 |
| EPS | 2.41 |
| Moving Average 50 Days | 54.92 |
| Moving Average 200 Days | 73.6 |
| Change | 2.1 |
If you invested $1000 in Lantheus Holdings, Inc. (LNTH) 10 years ago, it would be worth $15,987.08 as of December 04, 2025 at a share price of $61.87. Whereas If you bought $1000 worth of Lantheus Holdings, Inc. (LNTH) shares 5 years ago, it would be worth $4,502.91 as of December 04, 2025 at a share price of $61.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lantheus to Present Florbetaben F 18 Data at CTAD 2025
GlobeNewswire Inc.
Nov 24, 2025 1:30 PM GMT
BEDFORD, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient out
Lantheus Announces Leadership Transition Plan
GlobeNewswire Inc.
Nov 06, 2025 12:00 PM GMT
Brian Markison to Retire as Chief Executive Officer; Board Conducting Search for Next CEO Continued Execution of Company’s Strategy to be Led by Prior CEO Mary Anne Heino as Executive Chairperson BEDFORD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) --
Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
GlobeNewswire Inc.
Oct 30, 2025 12:30 PM GMT
PDUFA Date Set for March 29, 2026BEDFORD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disea